Avaliação do potencial de nanodispersões de cristal líquido funcionalizadas com cetuximabe na veiculação de docetaxel para o tratamento do câncer de próstata /

Avaliação do potencial de nanodispersões de cristal líquido funcionalizadas com cetuximabe na veiculação de docetaxel para o tratamento do câncer de próstata /

Orientador: Marlus Chorilli === Resumo: O câncer de próstata (CP) é a segunda neoplasia mais frequente entre homens no Brasil e é caracterizado por não apresentar sintomas em seus estágios iniciais, sendo diagnosticado em seu estágio avançado, o que muitas vezes dificulta o tratamento. Alguns fatore...

Full description

Bibliographic Details
Main Author:	Trevizan, Lucas Noboru Fatori
Other Authors:	Universidade Estadual Paulista "Júlio de Mesquita Filho" Faculdade de Ciências Farmacêuticas.
Format:	Others
Language:	Portuguese
Published:	Araraquara, 2018
Subjects:	nanodispersão de cristal líquido cetuximabe docetaxel câncer de próstata liquid crystalline nanodispersion cetuximab prostate cancer
Online Access:	http://hdl.handle.net/11449/157268

Similar Items

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts
by: Sreeranganathan M, et al.
Published: (2017-09-01)

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions
by: Joël Guigay, et al.
Published: (2019-08-01)

Recurrent squamous cell carcinoma of the skin treated successfully with single agent cetuximab therapy
by: Seber S, et al.
Published: (2016-02-01)

Organizing pneumonia secondary to cetuximab in a patient with colorectal cancer
by: Abdulaziz AlGhulayqah, et al.
Published: (2019-09-01)

Nanodispersões de fase líquido-cristalina como carreadoras de siRNA no tratamento tópico da psoríase: Avaliação em modelos in vitro e in vivo
by: Depieri, Lívia Vieira
Published: (2016)

Caracterização e aplicação de nanodispersão de bixina
by: Rafael Teruiti de Oliveira Takamoto
Published: (2015)

Caracterização e aplicação de nanodispersão de bixina
by: Takamoto, Rafael Teruiti de Oliveira
Published: (2015)

Avaluació preclínica de l'efecte antitumoral de cetuximab sobre la malaltia microscòpica residual post-radioteràpia
by: Pueyo Castells, Gemma
Published: (2010)

Tracheal cancer treated with a short course of external and endoluminal radio-chemotherapy combined with cetuximab – a case report
by: Michael I. Koukourakis, et al.
Published: (2010-01-01)

Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells
by: S. Zhang, et al.
Published: (2017-11-01)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
by: Sadamoto Zenda, et al.
Published: (2019-01-01)

Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells
by: Na Song, et al.
Published: (2014-04-01)

Cetuximab in first line treatment of metastatic colorectal cancer
by: Carlo Barone, et al.
Published: (2012-07-01)

Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?
by: Giuliani Jacopo, et al.
Published: (2014-04-01)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
by: Wing-Lok Chan, et al.
Published: (2014-01-01)

Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer
by: CHENG Jianping, et al.
Published: (2020-07-01)

Resveratrol Sensitizes Colorectal Cancer Cells to Cetuximab by Connexin 43 Upregulation-Induced Akt Inhibition
by: Yijia Wang, et al.
Published: (2020-04-01)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
by: Hanna Barmettler, et al.
Published: (2012-08-01)

Chemotherapeutic Effectiveness of Combining Cetuximab for Metastatic Colorectal Cancer Treatment: A System Review and Meta-Analysis
by: Rong Li, et al.
Published: (2020-05-01)

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
by: Dahan Laetitia, et al.
Published: (2011-11-01)

A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
by: Markus Hecht, et al.
Published: (2021-07-01)

Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
by: Karolin Ebert, et al.
Published: (2020-10-01)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
by: Yuri Ueda, et al.
Published: (2020-10-01)

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications
by: Kohei Shitara, et al.
Published: (2010-07-01)

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck
by: Schmitz Sandra, et al.
Published: (2015-03-01)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
by: Andrea Uhlyarik, et al.
Published: (2020-03-01)

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer
by: Lin Wang, et al.
Published: (2017-11-01)

Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer
by: Ying-nan Yang, et al.
Published: (2018-10-01)

Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts
by: De Tursi M, et al.
Published: (2017-06-01)

Interleukin-1 signaling contributes to the anti-tumor efficacy of Cetuximab in head and neck squamous cell carcinoma
by: Espinosa-Cotton, Madelyn
Published: (2018)

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
by: Andrea Botticelli, et al.
Published: (2021-07-01)

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab
by: Takehito Ehara, et al.
Published: (2020-02-01)

A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer
by: Nieder Carsten, et al.
Published: (2012-01-01)

Influence of HER2 Overexpression on Response to Cetuximab in Patients with Metastatic Colorectal Cancer, Tehran, Iran
by: Rambod MOZAFARI, et al.
Published: (2018-06-01)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
by: Hiroya Taniguchi, et al.
Published: (2020-06-01)

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
by: Cheng, C.-L, et al.
Published: (2022)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
by: Mengping Zhang, et al.
Published: (2020-06-01)

Aplicação tópica de lipossomas contendo cetuximabe: efeito do uso de métodos físicos de penetração cutânea no carcinoma celular escamoso de pele
by: Petrilli, Raquel
Published: (2017)

Osteopontin Mediates Cetuximab Resistance via the MAPK Pathway in NSCLC Cells
by: Cui J, et al.
Published: (2019-11-01)

Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
by: Akira Ooki, et al.
Published: (2020-03-01)